Mashup Score:18
OncLiveFDA Approves Sacituzumab Govitecan for Pretreated HR+/HER2– Metastatic Breast Cancer - 4 days
Mashup Score:18
Mashup Score:18
OncLiveFDA Approves Sacituzumab Govitecan for Pretreated HR+/HER2– Metastatic Breast Cancer - 4 days
Mashup Score:18
Mashup Score:12
OncLiveMridula George, MD, discusses the methods used to evaluate cardiotoxicity associated with adjuvant trastuzumab emtansine plus concurrent radiation therapy, and explains implications on the...
Adjuvant trastuzumab emtansine plus concurrent radiation therapy did not result in cardiotoxicities in patients with early-stage HER2-positive breast cancer. @MridulaGeorgeMD @RWJBarnabas #bcsm #oncology https://t.co/Id3kQqgT9D https://t.co/Id3kQqgT9D - view on twitter
Mashup Score:9
OncLiveBreast Cancer Expert Focuses on Decoding Biomarkers - 5 days
Mashup Score:9
For Kevin Kalinsky, MD, MS, director of breast medical oncology at the Winship Cancer Institute of Emory University in Atlanta, Georgia, his work on...
Breast Cancer Expert Focuses on Decoding Biomarkers @KalinskyKevin @jhaveri_komal @jane_meisel @YAbdouMD @jsparano @WinshipAtEmory @MSKCancerCenter @UNC_Lineberger @TischCancer #bcsm https://t.co/6FGIBFkUQI - view on twitter
Mashup Score:9
OncLiveImmunotherapy Propels Urothelial Carcinoma Treatment Advances - 5 days
Mashup Score:9
Stephanie A. Berg, DO, discussed the implications of these findings on the urothelial cancer treatment paradigm and how updated results may further influence the...
Immunotherapy Propels Urothelial Carcinoma Treatment Advances @bergsa83 @DanaFarber #oncology #medtwitter https://t.co/ppwU4exk32 - view on twitter
Mashup Score:8
OncLiveNeoadjuvant Pembrolizumab Elicits Deep Responses in Localized MSI-H/dMMR Solid Tumors - 1 week
Mashup Score:8
Neoadjuvant pembrolizumab was found to have high clinical activity and an acceptable safety profile in patients with localized microsatellite instability–high/deficient mismatch repair solid...
Neoadjuvant Pembrolizumab Elicits Deep Responses in Localized MSI-H/dMMR Solid Tumors @MDAndersonNews @JCO_ASCO #oncology #MedTwitter https://t.co/hUZmQlPoFw - view on twitter
Mashup Score:8
OncLiveMutation Status Drives PARP Inhibitor Investigation and Treatment in mCRPC - 1 day
Mashup Score:8
Atish D. Choudhury, MD, PhD, discussed the significance of these trials within the metastatic castration-resistant prostate cancer treatment landscape, highlighted investigative PARP inhibitor combinations,...
PARP inhibitors as monotherapies or in combination with AR pathway inhibitors may broaden treatment options for patients with mCRPC) with gene alterations within the homologous recombination–deficient pathwa. @DanaFarber #pcsm #oncology https://t.co/rr5t2dPC03 https://t.co/rr5t2dPC03 - view on twitter
Mashup Score:8
OncLiveKEYNOTE-991 Trial of Pembrolizumab Plus Enzalutamide/ADT in mHSPC to Stop for Futility - 1 week
Mashup Score:8
Merck is discontinuing the phase 3 KEYNOTE-991 trial evaluating pembrolizumab plus enzalutamide and androgen deprivation therapy vs placebo plus enzalutamide/ADT in patients with metastatic...
Merck is discontinuing the phase 3 KEYNOTE-991 trial evaluating pembrolizumab plus enzalutamide and androgen deprivation therapy vs placebo plus enzalutamide/ADT in patients with metastatic hormone-sensitive prostate cancer due to futility. #pcsm #oncology https://t.co/H4O4P0WVwn https://t.co/H4O4P0WVwn - view on twitter
Mashup Score:7
OncLiveCombinations Targeting EGFR and KRAS G12C May Advance NSCLC Treatment - 4 days
Mashup Score:7
Timothy Burns, MD, PhD, discusses the evolution of EGFR-targeted non–small cell lung cancer treatments, the importance of delineating small cell lung cancer subtypes, and...
Combinations Targeting EGFR and KRAS G12C May Advance NSCLC Treatment @UPMCHillmanCC @OncLiveSOSS #lcsm #OncLiveIPC https://t.co/EdyPzDfAN7 - view on twitter
Mashup Score:6
OncLiveMridula George, MD, discusses the methods used to evaluate cardiotoxicity associated with adjuvant trastuzumab emtansine plus concurrent radiation therapy, and explains implications on the...
Adjuvant T-DM1 Plus Concurrent Radiation Not Associated With Increased Cardiotoxicity in HER2+ Breast Cancer @MridulaGeorgeMD @RutgersCancer @RWJMS @SABCSSanAntonio #bcsm #SABCS22 https://t.co/qGRnx9d7Qg https://t.co/qGRnx9d7Qg - view on twitter
Mashup Score:6
OncLiveZolbetuximab Plus Chemo Extends PFS and OS in CLDN18.2+ Metastatic Gastric Cancer - 1 week
Mashup Score:6
Zolbetuximab demonstrated a survival benefit and a tolerable safety profile when combined with mFOLFOX6 vs mFOLFOX6 plus placebo in patients with CLDN18.2-positive, HER2-negative locally...
Zolbetuximab demonstrated a survival benefit when combined w/ mFOLFOX6 vs mFOLFOX6 + placebo in CLDN18.2-positive, HER2-negative locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma. @KoheiShitara #oncology https://t.co/bVbJF79yUs - view on twitter
The FDA has approved sacituzumab govitecan-hziy (Trodelvy) for the treatment of adult patients with unresectable locally advanced or metastatic hormone receptor–positive, HER2-negative breast cancer...
BREAKING: @US_FDA Approves Sacituzumab Govitecan for Pretreated HR+/HER2– Metastatic Breast Cancer #bcsm #oncology https://t.co/n4ZkhKiFB0 https://t.co/n4ZkhKiFB0 - view on twitter